|
HIV patients with PAH: Results of treatment with Tracleer Actelion release ALLSCHWIL/BASEL, SWITZERLAND - 2 September 2003 - Actelion Ltd (SWX: ATLN) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA) Tracleer® (bosentan) in the treatment of pulmonary arterial hypertension (PAH) related to HIV (human immunodeficiency virus) infection. Phase IIIb study presented today at the annual European Society of Cardiology meeting in Vienna, Austria.
—Posted: September 2, 2003
More news headlines: This week | Last week | Search archive
|
